


ABAC THERAPEUTICS

Precision antimicrobial agents



There is growing awareness and fear, both from governments and the general public, of the dangers of infections caused by pathogens that are resistant to current antibiotics, and of the lack of new drugs to treat these infections.

ABAC Therapeutics is a spin-out from the Spanish pharmaceutical company Ferrer, that is focused on the discovery and development of first-in-class, novel mechanism, pathogen-specific antibacterial drugs to treat multi-drug resistant infections. ABAC's proprietary discovery platform, *PasNas*, increases the probability of discovering such new pathogen-specific drugs.

Focus on pathogen-specific antibacterial compounds

ABAC Therapeutics foresees that personalized (or precision) treatments using pathogen-specific antibacterial agents with novel mechanisms of action will constitute the next generation of anti-infective treatments because they kill exclusively infecting bacteria whilst keeping at a minimum the impact on normal flora, the use in animal treatment, and therefore

in the selection of resistant strains, and minimize any treatment-induced co-morbidities, such as untoward effects on the human microbiota.

Focusing on discovering compounds that target a single species has a better chance of succeeding. Optimizing compounds that target common features amongst phylogenetically disparate species (broad spectrum) is far more difficult than exploiting specific differences in physiology or virulence mechanisms between them.

Soon, point of care diagnostic techniques will be rapid, cost-effective and widely used. In the future, we think that precision antimicrobial agents (pathogen-specific and narrow spectrum) will replace broad spectrum antibiotics.

PasNas, a new pre-clinical technology

Developed by the ABAC founders, *PasNas* is a highly scalable and multiplex platform designed to characterize and identify high quality leads, *PasNas* increase the probability of produce candidates to maximize the probability of success in clinical development.

PasNas will reduce anti-infective drug attrition rates and cut development costs by ensuring that compounds with the best overall therapeutic and pharmaceutical properties and, not just those with the most potency, are progressed at each stage-gate decision. The *PasNas* platform has been validated twice, with a novel antimalarial candidate and one pre-candidate against *Acinetobacter*.

ABAC organization

ABAC Therapeutics is structured on a consortium of investors and private and

public institutions on a risk sharing model, constituting a multidisciplinary team of people with experience and with the attitude and values to achieve success. All and always focused on productivity and delivery.

Why ABAC Therapeutics now?

The ABAC business model is designed to sustain and strengthen its core competence: drug discovery and early development of pathogen-specific antibacterial agents. The Company plans to discover and progress candidates into early clinical phases, after which point it will out-license or sell individual products/ programs, thereby creating a valuable and self-sustaining drug discovery platform.

The convergence of high unmet medical need, lack of competition, regulatory easing and the desire to bring personalized medicine to anti-infective therapy provides great opportunity for drug developers in the area of infectious diseases.

ABAC Therapeutics is committed to the fight against infectious diseases, combining radical innovation in product (precision antibacterial agents, precision medicine), with a new drug discovery strategy (*PasNas*), and structured on an organization based on the commitment of all stakeholders, focused on productivity and delivery.



Pathogen-specific agents will minimize impact on human microbiota, in animal treatment, and therefore in the selection of resistant strains



Domingo Gargallo-Viola
Co-Founder and CSO
Joan XXIII, 10
E-08950 Esplugues de Llobregat
Barcelona, Spain
T: +34 93 509 32 31
F: +34 93 411 27 64
M: +34 648 19 96 22
dgargallo@abactherapeutics.com
http://www.abactherapeutics.com



Some ABAC Therapeutics team members. Catalina Chauan, Albert Palomer (founder), Domingo Gargallo-Viola (founder) and Soraya Ortiz